Structure Therapeutics (NASDAQ:GPCR) Stock Rating Lowered by Wall Street Zen

Structure Therapeutics (NASDAQ:GPCR) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other equities research analysts have also recently weighed in on the company. BMO Capital Markets set a $145.00 price objective on Structure Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. The Goldman Sachs Group raised Structure Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 20th. Citizens Jmp dropped their target price on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating for the company in a report on Friday, February 27th. Wolfe Research started coverage on Structure Therapeutics in a research report on Thursday. They set a “peer perform” rating on the stock. Finally, Morgan Stanley increased their price target on Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.00.

Structure Therapeutics Stock Down 0.6%

Shares of NASDAQ:GPCR opened at $45.92 on Friday. The firm has a fifty day simple moving average of $68.79 and a two-hundred day simple moving average of $51.39. Structure Therapeutics has a 52 week low of $13.22 and a 52 week high of $94.90. The stock has a market capitalization of $3.25 billion, a P/E ratio of -58.13 and a beta of -1.80.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.14). On average, analysts expect that Structure Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of Structure Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Osaic Holdings Inc. grew its stake in shares of Structure Therapeutics by 101.9% during the second quarter. Osaic Holdings Inc. now owns 63,362 shares of the company’s stock valued at $1,314,000 after buying an additional 31,972 shares during the last quarter. Aberdeen Group plc lifted its stake in shares of Structure Therapeutics by 46.1% during the 3rd quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock worth $16,432,000 after acquiring an additional 185,245 shares during the last quarter. Jefferies Financial Group Inc. purchased a new position in Structure Therapeutics during the 3rd quarter valued at $4,770,000. Birchview Capital LP purchased a new position in Structure Therapeutics during the 2nd quarter valued at $747,000. Finally, Private Capital Advisors Inc. bought a new position in Structure Therapeutics in the 3rd quarter valued at $1,545,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.